Immunoassay and ELISA Technique Training for Biomedical Scientists
Immunoassays sit at the heart of modern clinical pathology. From thyroid function and cardiac troponin to infectious-disease serology and autoantibody panels, much of what a biomedical scientist (BMS) reports each day depends on an antibody recognising its target with exquisite specificity. That specificity is also the weakness: when something other than the analyte binds the assay antibodies, the result can be badly wrong while looking perfectly normal. This guide explains the core immunoassay formats, how the enzyme-linked immunosorbent assay (ELISA) and automated chemiluminescent platforms generate a signal, how calibration converts that signal into a concentration, and — most importantly for patient safety — how to recognise and mitigate the interferences that catch laboratories out. It is written for NHS trainees and registered scientists across Bands 2 to 8.
How an Immunoassay Works
An immunoassay measures an analyte by exploiting the highly specific binding between an antibody and its antigen (the analyte, or a region of it called an epitope). To turn that binding event into a measurable number, the assay attaches a label — historically an enzyme, now more often a chemiluminescent molecule — to one of the binding partners. The amount of label captured at the end of the reaction is detected as colour, light or current, and that signal is related to the analyte concentration through a calibration curve.
Every immunoassay therefore needs three things: a specific antibody (the reagent), a solid phase to separate bound from unbound material (a microplate well, or a magnetic microparticle in automated systems), and a detection system (the label and a means of reading it). The way these elements are arranged defines the assay format, and the format determines how the assay behaves when something goes wrong.
Immunoassay Formats: Sandwich, Competitive and Indirect
There are three formats every BMS must be able to describe and distinguish, because they fail in opposite directions.
Sandwich (two-site immunometric) assays capture the analyte between two antibodies that bind different epitopes: a plate- or particle-bound capture antibody and a labelled detection antibody. The analyte is "sandwiched" between them, and the signal is directly proportional to analyte concentration. Sandwich formats are sensitive, specific and the most widely used arrangement for larger molecules such as TSH (thyroid-stimulating hormone), troponin and most protein hormones. They require the analyte to carry at least two distinct epitopes, so they are unsuitable for very small molecules.
Competitive (inhibition) assays are used for small molecules with a single epitope, such as steroid hormones, vitamin D and many drugs. Here a fixed, limited amount of antibody is offered both the patient's analyte and a labelled version of the analyte, which compete for the binding sites. The more analyte in the sample, the less labelled material binds, so the signal is inversely proportional to concentration — high analyte gives a low signal.
Indirect assays detect antibodies rather than antigens, and are the workhorse of serology and autoimmunity. The target antigen is fixed to the solid phase, the patient's antibody binds it, and an enzyme-conjugated anti-human secondary antibody is added to generate signal. Because each captured antibody can bind several secondary conjugates, the format amplifies the signal. A direct ELISA is the simplest variant, using a single labelled primary antibody with no secondary step.
| Format | Detects | Signal vs analyte | Typical NHS use | Key vulnerability | |--------|---------|-------------------|-----------------|-------------------| | Sandwich (immunometric) | Larger antigens (≥2 epitopes) | Directly proportional | TSH, troponin, hCG, ferritin | Hook effect; heterophile bridging | | Competitive | Small molecules (1 epitope) | Inversely proportional | Cortisol, vitamin D, oestradiol | Inverse bias from interferents | | Indirect | Antibodies in patient sample | Directly proportional | Infectious serology, autoantibodies | Cross-reactivity; non-specific binding | | Direct | Antigen with labelled primary Ab | Directly proportional | Confirmatory / research steps | Lower sensitivity, no amplification |
ELISA in Practice: A Worked Sandwich Procedure
Although NHS routine work is now dominated by automated analysers, the manual ELISA remains a teaching cornerstone and is still used for some specialist autoimmunity and allergy assays. Understanding the wet-bench steps makes the automated equivalent far easier to troubleshoot. A typical two-step sandwich ELISA runs as follows.
1. Coat the microplate wells with capture antibody and incubate so it adsorbs to the plastic. 2. Block the remaining surface with an inert protein (for example bovine serum albumin) to stop later reagents sticking non-specifically. 3. Add sample and calibrators, incubate, then wash thoroughly to remove unbound material. Washing is the single most common source of poor ELISA performance. 4. Add the labelled detection antibody, incubate, then wash again. 5. Add substrate (for an enzyme label such as horseradish peroxidase, a chromogen like TMB), allowing colour to develop in proportion to bound enzyme. 6. Stop the reaction and read the optical density on a plate reader at the specified wavelength. 7. Reduce the data by fitting the calibrator signals to a curve and reading patient concentrations from it.
The deliberate wash steps in this two-step design are not just housekeeping — as we will see, they are also the main defence against the high-dose hook effect.
Automated Chemiluminescent Platforms
Most high-throughput NHS immunoassay testing now runs on automated chemiluminescent immunoassay (CLIA) or electrochemiluminescent immunoassay (ECLIA) analysers rather than enzyme/colour ELISA. The underlying immunology is identical — sandwich or competitive binding on a solid phase — but the label and solid phase change.
- The solid phase is usually a paramagnetic microparticle held in place by a magnet during washing, giving fast, efficient separation in a closed system.
- In CLIA, the label is a chemiluminescent molecule such as an acridinium ester, which emits a brief "flash" of light when triggered with peroxide and alkali. The light output is measured by a luminometer.
- In ECLIA, a ruthenium complex label generates a sustained "glow" of light when an electrical current is applied at an electrode in the presence of tripropylamine.
Calibration and Traceability
A raw signal means nothing until it is converted to a concentration. Immunoassay calibration uses a set of calibrators of known concentration, run to generate a calibration curve. Because antibody binding saturates at the extremes, the relationship is rarely a straight line; it is sigmoidal, and is most commonly modelled with a four-parameter logistic (4PL) function (a five-parameter logistic, 5PL, is used where the curve is asymmetric). The analyser fits the curve, then interpolates each patient signal to read off a concentration.
Practical points the BMS must own:
- Recalibrate when reagent lots change, after major maintenance, when internal quality control (IQC) drifts, or at the interval specified by the manufacturer.
- Results beyond the highest calibrator are not reliable extrapolations — they must be diluted and re-assayed within the measuring range.
- Calibrators should be traceable to a recognised reference material or method where one exists, supporting comparability between laboratories, as expected under ISO 15189:2022.
- IQC at clinically relevant concentrations, plus participation in external quality assessment (EQA), confirms the calibration is holding day to day.
Recognising and Mitigating Interferences
Interferences are the reason immunoassay results must always be read against the clinical picture. The three that every immunology and biochemistry BMS should be able to discuss in detail are the high-dose hook effect, heterophile/human anti-animal antibodies, and biotin interference.
The High-Dose Hook Effect
In a sandwich assay, the signal normally rises with analyte. But at extremely high analyte concentrations the capture antibody and the labelled detection antibody can each become saturated separately, so the intact analyte-bridged sandwich fails to form. The signal, having risen, then falls — "hooks" downward — and the analyser reports a falsely low (sometimes normal-looking) result for a grossly elevated analyte. Classic clinical traps include very high hCG in molar pregnancy or germ-cell tumours, prolactin in macroprolactinomas, and high ferritin.
The hook effect is predominantly a problem of one-step assays, where sample and detection antibody are incubated together. Mitigations:
- Prefer two-step designs with a wash between sample and conjugate, which physically removes excess unbound analyte.
- Re-assay suspect samples at dilution: if a "normal" result rises markedly on dilution, the undiluted sample was hooked.
- Use automated flagging of non-linear or out-of-pattern responses, and always correlate with the clinical presentation when a result seems implausibly low for the picture.
Heterophile and Human Anti-Animal Antibodies
Heterophile antibodies are endogenous human antibodies with broad, weak reactivity against animal immunoglobulins; the more specific human anti-animal antibodies (HAAA) — most famously human anti-mouse antibodies (HAMA), but also anti-goat, anti-sheep and anti-rabbit — arise after exposure to animal proteins, mouse-derived therapeutics or imaging agents. In a sandwich assay these antibodies can bridge the capture and detection antibodies directly, mimicking a real sandwich and producing a false positive (and occasionally a false negative). In a competitive assay they may bind the assay antibody and distort the result.
Detection and mitigation:
- Serial dilution: a genuine result dilutes linearly; interference typically shows non-linearity (loss of parallelism).
- Heterophile blocking tubes / blocking reagents: a clinically significant shift (commonly taken as a fall of more than ~20%) after blocking supports interference.
- Re-test on an alternative platform using different antibodies; a markedly different result points to an assay-specific interferent.
- Manufacturers mitigate at source using blocking reagents, antibody fragments (removing the Fc region that heterophiles often target) and non-mammalian capture/detection antibodies. These tools reduce, but do not always eliminate, interference, so vigilance remains essential.
Biotin Interference
Many automated platforms use the very strong biotin–streptavidin bond to immobilise reagents. When a patient takes high-dose biotin (vitamin B7, common in over-the-counter hair, skin and nail supplements, and prescribed at high doses in some metabolic and neurological conditions), the free biotin in the sample competes with the assay's biotinylated reagents for the streptavidin solid phase. The direction of error depends on format:
- In sandwich assays the biotinylated antibody-analyte complex is lost at the wash step, giving a falsely low result.
- In competitive assays the labelled biotinylated analyte is displaced, giving a falsely high result.
- Ask about supplements as part of the clinical query when results do not fit, and document the enquiry.
- Retest after a washout period off biotin (the appropriate interval depends on dose and renal function; follow local and manufacturer guidance) once supplementation has stopped.
- Use biotin depletion (pre-treating the sample with streptavidin microparticles) or a newer-generation assay designed to tolerate higher biotin concentrations.
- Note the manufacturer's stated biotin tolerance threshold in the instructions for use (IFU) when assessing whether a result is trustworthy.
Quality, Verification and EQA in the NHS
No immunoassay should report patient results until the laboratory has verified its performance in its own hands. Under ISO 15189:2022, a laboratory introducing a manufacturer-validated assay must verify key performance characteristics — typically imprecision, trueness/bias against the IFU claims, the reportable (measuring) range, and a check on carryover and interferences relevant to the test — and record that the method is fit for its intended clinical use before go-live. Where an assay is modified or has no manufacturer claim, fuller validation is required.
Day to day, performance is held in check by IQC at clinically meaningful concentrations and by participation in external quality assessment. In immunology, UK NEQAS for Immunology, Immunochemistry & Allergy (IIA) — a UKAS-accredited proficiency-testing provider based at the Northern General Hospital in Sheffield and running EQA since 1982 — distributes samples across autoimmunity, immunochemistry, allergy and related schemes, letting laboratories benchmark against peers and catch method-specific bias. EQA performance is also part of the evidence UKAS reviews at assessment.